2020 VISTA is the Website for LPBI Group’s Ten Health Care Contents Asset Classes prospected for technology ownership transfer and monetization
2/1/2021
Milestone achieved today:
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Thought on the transition
One Possible Strategy for an Acquisition is via a SPAC
Follow the links
- Executive Summary
- Opportunities Map in the Acquisition Arena
- Dynamic Contents for LPBI Group’s PowerPoint Presentation
- Detailed Technology Description
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Top Authors by Number of eReaders Views
- Top Articles by Number of e-Readers for All Days ending 2019-02-17
- LPBI Group’s Social Media Presence
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Financial Advisory & Legal Advisory Providers: US & Israel
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- FIT Members Contribute to Opportunities Map
- FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
- Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
- LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
- FIT members – Who works on WHAT?
- Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
- MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
- JOURNAL Statistics on 2/24/2019
- Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
- REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
- 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis
- Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
- LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
- WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
- For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
- The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
- e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
- Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers
9/25/2020
1.0 & 2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
8/19/2020
An UPDATE Shared with ALL
We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:
- Breakthrough News Corner
- Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
- An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
- Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
- Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
- Voices of Global Citizens: Impact of The Coronavirus Pandemic, Gail S. Thornton, M.A. Lead Curator – e–mail Contact: gailsthornton@yahoo.com
- Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection, Aviva Lev-Ari, PhD, RN Lead Curator e-mail contact: avivalev-ari@alum.berkeley.edu
- Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts: oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu
That effort took 2 months of most intensive work on my part.
STATEMENT
- The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
- In the INTERIM awaiting for more favorable conditions on the market
- we invested in INTERNAL development of IP
We launched FOUR additional PORTALS:
- Artificial Intelligence in Genomics & Cancer
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
- 2020 Summer Internship Portal
https://pharmaceuticalintelligence.com/2020-summer-internship/
- Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- 2021 Medical Text Analysis (NLP)
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
- The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health
Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:
- Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2
Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery:
TNS #6: e-Books Translations into Japanese, Spanish, Russian
These are two distinctive entities
2.0 LPBI, 1/2021 – 12/2025 – TNS #1,2,3,4,5,6, above. Executive Summary
https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/
1.0 LPBI, 4/2012 – 12/2020 – Executive Summary
https://pharmaceuticalintelligence.com/home-website-front-page/
Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models
RED & BLUE Lines
A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020
RED Line – A Marked Point Process Model: $48MM for Journal Valuation
BLUE Line – A Conservative Assumption-based Growth Prediction (Joel)
vs
BROWN & GREEN Lines
B. No New Articles after 12/2020 will be published
BROWN Line – A Marked Point Process Model – Assuming Last article published on 12/31/2020
GREEN Line – A Conservative Assumption-based Growth Prediction (Joel) – Assuming Last article published on 12/31/2020
Data Source:
WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020
[for the Annual 2020 data: the first 6 months x2].
4/2012 – 12/2020 – ACTUALS
2021 – 2025 – FORECAST 
Our portfolio of Intellectual Property (IP) include TEN asset classes
| Asset Classes | Type | Quantity |
|
Asset Class I |
The Journal
9/25/2020 Views 1,829,736
|
5,924 articles on 9/25/2020 Valuation [$XXM] done by Joel on Alex WP Data ____________ |
|
Asset Class II |
BioMed e-Series | 16 volumes
Valuation [$5M] done by Joel & Aviva August 2020 121,547 page downloads in total on 8/31/2020. This number represents the equivalent of 52 books to have been sold [KENP to Book] ____________ |
|
Asset Class III |
eProceedings | 60 events
Valuation [$1.4M] done by Dr. Williams & Aviva ____________ |
|
Asset Class IV |
Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:
https://pharmaceuticalintelligence.com/coronavirus-portal/
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
https://pharmaceuticalintelligence.com/2020-summer-internship/
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
|
$6MM |
|
Asset Class V |
Gallery of Biological Images in use in Articles and Books | 5,100 Biological images in the Journal’s Media Gallery
____________ |
|
Asset Class VI |
Team of Experts
See Platform: • Knowledge Platform System (KPS) https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
BIOs Final Improvement Team (FIT)
$3MM
____________ |
|
Asset Class VII |
Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale | August 2020 121,547 page downloads in total on 8/31/2020. This number represents the equivalent of 52 books to have been sold [KENP to Book]
____________ |
|
Asset Class VIII |
Subscribers to the Website |
2,549 on 8/18/2020
____________ |
|
Asset Class IX |
INTANGIBLE ASSETS & Intrinsic Value = Good Will | TBD |
|
Asset Class X |
e-VOICES PODCASTING – Audio Library
e-VOICES Podcasting, 2019 – 2021 |
Shared FREE like industry standard |
We estimate revenue potential of each entity to be
~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]
- Graph above present the Valuation of IP Asset Class I
~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]
~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI
The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy
- ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
- Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
- Our Podcast Library is growing – See Table, below
Development Plan for e-VOICES Podcasting, 2019 – 2021*
https://pharmaceuticalintelligence.com/audio-podcasts/
| Podcast Interviewer | INTERVIEWEE(S) | Subject | Date | Audio/Video/
Narrator |
| Gail S. Thornton | Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari | 3D BioPrinting in Medicine | 5/2019 | Audio |
| Gail S. Thornton | Prof. Feldman | Evolution Biology and Population Genetics | 3/17/2020 | Audio |
| Gail S. Thornton | Dr. Larry H. Bernstein, MD, FCAP | Life Memoirs in Clinical Pathology Told | 10/12/2020 | Audio
Narrator: Dr. S.J. Williams |
| Gail S. Thornton | Dr. Sudipta Saha | Research in Reproductive Technology | 11/7/2020 | Audio |
| Gail S. Thornton | Dr. Justin D. Pearlman, MD, PhD | Cardiac Imaging – Evolution of Diagnostic Methods | 4Q 2020 | Audio |
| Gail S. Thornton | Dr. Raphael Nir | From Big Pharma to Biotech Entrepreneurship | 2021 | Audio |
| Gail S. Thornton | Dr. Meg Baker | GlycoBiology in Practice | 2021 | Audio |
| Gail S. Thornton | Dr. Ofer Markman | Memories of
Procognia |
2021 | Audio |
| Gail S. Thornton | Dr. Irina Robu | AI & Tissue Engineering | 2021 | Audio |
| Gail S. Thornton | Dr. Williams | Preferably 3rd party interviewer sourced by Gail. Topic: AI & Genomics | 2021 | Audio |
| Gail S. Thornton | Dr. Aviva Lev-Ari | Preferably 3rd party interviewer sourced by Gail. Topic: Curation & ML | 2021 | Audio |
Schedule for 2021 Newsletters posted https://pharmaceuticalintelligence.com/newsletter/
DETAILS about IP Asset Class I: LPBI Journal, IP Asset Class II: BioMed e-Series and IP Asset Class III: Biotech & Medical Conference e-Proceedings and Tweet Collections
Our VAST intellectual property (IP) portfolio includes three asset classes:
-
IP Asset Class I: LPBI Journal
+1.8Million eReaders, +5900 scientific articles, +700 categories of research
-
IP Asset Class II: BioMed e-Series
16 Volumes in Medicine
What make our e-Books UNIQUE: An Example
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. Published on 12/28/2019
- No other book covers the same topics in a single volume. In terms of synergy, this book combines:
1. Content curation in article format with embedded videos and audio podcasts
2. Conference e-Proceedings based on real-time coverage by the authors and editors of this book.
3. Archived tweets of quotes from speakers at leading Biotech conferences, posted in real-time by the same authors- It integrates in a single volume four distinct perspectives: (a) basic science, (b) technologies & methodologies, (c) clinical aspects, and (d) business and legal aspects.
- The material in this book represents the scientific frontier in Biological Sciences and Medicine related to the Genomics aspects of Disease Onset. It addresses:
1. All aspects of life: the Cell, the Organ, the Human Body and Human Populations
2. All methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-GenomicsArtificial Intelligence in Medicine is covered in Part 3 of the e-Book. 3.1 to 3.5 represent the frontier in this emerging field:
3.1 The Science
3.2 Technologies and Methodologies
3.3 Clinical Aspects
3.4 Business and Legal
3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset
- No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
- No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
- No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience
- No other book has 326 articles on the topics included in the Book’s title: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
-
IP Asset Class III: Biotech & Medical Conference e-Proceedings
Corpus of 70 events covered in real time yielding 60 e-Proceedings and 36 Tweet Collections
OTHER ASSET CLASSES: IV, V, VI, VII, X
- Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
- Asset Class V is a Gallery of 5,100 images used in the articles and books
- Asset Class VI is the Team of Experts
- Asset Class VII are the Royalties on BioMed e-Series:
- e-Book age down loads,
- e-Book borrowings and
- e-Book sale
- Asset Class X are the e-Voices Podcasting – Audio Podcasts Library https://pharmaceuticalintelligence.com/audio-podcasts/
Asset List showing Value:
@@@@@ TANGIBLE ASSETS:
1. The Journal has 1,829,736 eReaders on 9/25/2020 – ASSET CLASS I
— It has +5900 articles
— It demonstrates > 7500 comments by Scientists for +5900 articles
— It has +10K tags counted by the computer
— It has +700 categories of research in SIX disciplines among them the most complex are
- Cell signaling
- ATP
- Autophage
- Computational Biology and NGS
- Cardiac imaging
- Endosome
- Liposomes
— It has 2,549 subscribers on 8/18/2020
2. The BioMed e-Series – ASSET CLASS II
Royalties structure:
– 121,547 page downloads in total on 8/31/2020
– x book borrowing
– y book sale – suppressed by Unlimited Prima Membership: READ FOR FREE and Pay per view
– 65% of book sales revenues is retained by Amazon
3. e-Proceedings and Activity on Twitter.com – ASSET CLASS III
- LPBI is the One and only e-Proceedings generator at end of Conference by one-Click
- The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and Ranked #2: @AVIVA1950, respectively. Ranked #3 via @NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
@@@@@ INTANGIBLE ASSETS equal e-Reputations
A. Institutions following @AVIVA1950 and @pharma_BI include the marque organizations as follows:
- TECHNION
- WEIZMANN INSTITUTE
- HEBREW UNIV
- PARTNERS INNOVATIONS: MGH & BWH
- BROAD INSTITUTE @MIT & @Harvard
- Bayer US
- PhRMA
- Keck Medicine of USC
- Intermountain Cancer
- MassBio
- Hadasit Bio Holdings
- BioWorld
- Bell Labs
- BCM_CVRI
- MIT Spectrum
- TED Talks
B. LPBI’s Founder is followed by 500 CEOs 200 CEOs in Biotech & Pharma on LinkedIn and
C. LPBI’s Founder has ~7300 followers 1st level connection on LinkedIn.
Distribution of 1st level LinkedIn connection by Industry
| Chemicals | 2366 |
| Pharmaceuticals | 919 |
| Biotechnology | 841 |
| Oil & Energy | 664 |
| Staffing and Recruiting | 218 |
| Management Consulting | 218 |
| Research | 207 |
| Information Technology and Services | 198 |
| Environmental Services | 183 |
| Plastics | 171 |
| Food & Beverages | 137 |
| Marketing and Advertising | 115 |
| Human Resources | 96 |
| Food Production | 93 |
| Financial Services | 92 |
D. LPBI’s Founder is bestowed by >1000 endorsements
@@@@ LPBI Group’s Social Media Presence in 2020
Our Social Media Presence in 2020 is by two handles on Twitter.com
@pharma_BI
Official handle of my Venture: Leaders in Pharmaceutical Business Intelligence (LPBI) Group,
Boston, MA, NJ, CA, PA, ME, DE, India, Israel & Canada
@AVIVA1950
Personal account of Aviva Lev-Ari, PhD, RN – LPBI Group’s Founder
2019 World Medical Innovation Forum on AI in Medicine – Aviva’s rankings as Influencer
- The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
- For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
Follow the links
- Executive Summary
- Opportunities Map in the Acquisition Arena
- Dynamic Contents for LPBI Group’s PowerPoint Presentation
- Detailed Technology Description
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Top Authors by Number of eReaders Views
- Top Articles by Number of e-Readers for All Days ending 2019-02-17
- LPBI Group’s Social Media Presence
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Financial Advisory & Legal Advisory Providers: US & Israel
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- FIT Members Contribute to Opportunities Map
- FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
- Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
- LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
- FIT members – Who works on WHAT?
- Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
- MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
- JOURNAL Statistics on 2/24/2019
- Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
- REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
- 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis
- Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
- LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
- WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
- For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
- The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
- e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
- Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers
Our Team
- Aviva Lev-Ari, PhD, RN, Director and Founder
- Members of the Board
- Senior Editors
- Experts, Authors, Writers (EAWs)
- Business Development & Private Equity Investment
- Scientific Delegation Members & Patent Holders
- Inventors: Biologics
- Inventors: Medical Devices
- Research Assistants
- Research Associates
1.0 & 2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
This page has the following sub pages.
- Executive Summary
- Opportunities Map in the Acquisition Arena
- Dynamic Contents for LPBI Group’s PowerPoint Presentation
- Detailed Technology Description
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Top Authors by Number of e-Readers Views as of 2020-06-02
- Top Articles by Number of e-Readers for All Days ending 2020-06-02
- LPBI Group’s Social Media Presence
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Financial Advisory & Legal Advisory Providers: US & Israel
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- Final Improvement Team (FIT) Members Contribute to Opportunities Map & Define LPBI Uniqueness
- FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lasping of Active Status, COMPs Formulas
- HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
- LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
- Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
- MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
- FIT members – Who works on WHAT?
- Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers
- JOURNAL Statistics from Inception, Data retrieved on 2/24/2019
- e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views = Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
- Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
- REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
- 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis
- Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
- LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
- WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22